Communiqués Race Oncology Limited

Actions

Marché Fermé - Australian S.E. Autres places de cotation 08:10:13 28/06/2024			Varia. 5j.	Varia. 1 janv.
1,825 ^AUD	+1,11 %		-2,14 %	+117,26 %

20/06	Race Oncology nomme George Clinical pour l'essai de phase 1 du bisantrène RC220	MT
18/06	Race Oncology reçoit la désignation de maladie pédiatrique rare de la FDA américaine pour son médicament contre la leucémie	MT

Race Oncology's breakthrough in cancer cell treatment	15/05	AQ
Race Oncology looks to accelerate clinical development of bisantrene	28/02	AQ
Race Oncology appoints Dr Daniel Tillett as CEO	23/11	AQ
Race Oncology highlights impressive bisantrene clinical data	07/11	AQ
Race Oncology kicks off safety studies for RC220	09/10/23	AQ
Race Oncology at the heart of cancer care	09/08/23	AQ
Race Oncology announces deal with manufacturer Ardena to develop companyÃ¢€™s new IV formulation RC220	19/07/23	AQ
Race Oncology poised for observational heart protection breast cancer trial	14/03/23	AQ
Race Oncology tabs drug industry veteran Damian Clarke-Bruce as companyÃ¢€™s new Managing Director/CEO	15/12/22	AQ
Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO	15/12/22	EQ
Race Oncology welcomes positive pre-IND meeting for Zantrene	24/11/22	AQ
Race Oncology welcomes positive pre-IND meeting for Zantrene	24/11/22	EQ
Race Oncology : Update - Notification of buy-back - RAC	28/07/22	PU
Race Oncology : RAC Quarterly Investor Presentation	27/07/22	PU
Race Oncology : Update - Notification of buy-back - RAC	26/07/22	PU
Race Oncology : Quarterly Activity Report & Appendix 4C	22/07/22	PU
Race Oncology : EMD AML MDS Trial Expands to Europe	08/06/22	PU
Race Oncology : Quarterly Activity Report & Appendix 4C	21/04/22	PU
Race Oncology : Zantrene highly effective in EMD AML Mouse Model	16/03/22	PU
Race Oncology : ASX Small and Mid-Cap Conference Presentation	15/03/22	PU

Aucun résultat pour cette recherche